top of page
  • Grey Twitter Icon
  • Grey LinkedIn Icon
White Background

PUBLICATIONS

​​

  1. Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities.
    Llorente A, Arora GK, Murad R, Emerling BM. Nat Rev Cancer. 2025 Jun;25(6):463-487. doi: 10.1038/s41568-025-00810-1. Epub 2025 Apr 3. Review. PubMed PMID: 40181165. 
     

  2. Noncanonical PI(4,5)P(2) coordinates lysosome positioning through cholesterol trafficking.
    Loughran RM, Arora GK, Sun J, Llorente A, Crabtree S, Ly K, Huynh RL, Cho W, Emerling BM.  bioRxiv. 2025 Jan 3;. doi: 10.1101/2025.01.02.629779. PubMed PMID: 39803512; PubMed Central PMCID: PMC11722365. 
     

  3. Loss of PI5P4Kα Slows the Progression of a Pten Mutant Basal Cell Model of Prostate Cancer.
    Triscott J, Lehner M, Benjak A, Reist M, Emerling BM, Ng CKY, de Brot S, Rubin MA.  Mol Cancer Res. 2025 Jan 2;23(1):33-45. doi: 10.1158/1541-7786.MCR-24-0290. PubMed PMID: 39382632; PubMed Central PMCID: PMC7616865. 
     

  4. Hippo and PI5P4K signaling intersect to control the transcriptional activation of YAP.
    Palamiuc L, Johnson JL, Haratipour Z, Loughran RM, Choi WJ, Arora GK, Tieu V, Ly K, Llorente A, Crabtree S, Wong JCY, Ravi A, Wiederhold T, Murad R, Blind RD, Emerling BM.  Sci Signal. 2024 May 28;17(838):eado6266. doi: 10.1126/scisignal.ado6266. Epub 2024 May 28. PubMed PMID: 38805583; PubMed Central PMCID: PMC11283293. 
     

  5. Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention.
    Llorente A, Loughran RM, Emerling BM.  Front Cell Dev Biol. 2023;11:1297355. doi: 10.3389/fcell.2023.1297355. eCollection 2023. PubMed PMID: 37954209; PubMed Central PMCID: PMC10634348. 
     

  6. Activation of p53-regulated pro-survival signals and hypoxia-independent mitochondrial targeting of TIGAR by human papillomavirus E6 oncoproteins.
    Yapindi L, Bowley T, Kurtaneck N, Bergeson RL, James K, Wilbourne J, Harrod CK, Hernandez BY, Emerling BM, Yates C, Harrod R. Virology. 2023 Aug;585:1-20. doi: 10.1016/j.virol.2023.05.004. Epub 2023 May 22. PubMed PMID: 37257253; PubMed Central PMCID: PMC10527176. 
     

  7. Beyond PI3Ks: targeting phosphoinositide kinases in disease.
    Burke JE, Triscott J, Emerling BM, Hammond GRV. Nat Rev Drug Discov. 2023 May;22(5):357-386. doi: 10.1038/s41573-022-00582-5. Epub 2022 Nov 14. Review. PubMed PMID: 36376561; PubMed Central PMCID: PMC9663198. 
     

  8. PI5P4Kα exposes cancer survival vulnerability in prostate cancer metabolism through a mTORC1-AR signaling axis.
    Triscott J, Gallon J, Reist M, Lehner MM, Ravi A, Arora GK, Loughran RL, de Brot S, Gallart-Ayala H, Ivanisevic JL, Piscuoglio S, Cantley LC, Emerling BM, and Rubin MA. Sci Adv 2023 Feb 3;9(5):eade8641. PMID: 36724278; PMCID: PMC9891700
     

  9. PIP kinases: A versatile family that demands further therapeutic attention
    Llorente A, Arora GK, Grenier SF and Emerling BM. Adv Biol Regul 2022 Dec 5: 100939. PMID: 36517396.
     

  10. Beyond PI3Ks: targeting phosphoinositide kinases in disease
    Burke JE, Triscott J, Emerling BM, Hammond GRV. Nat Rev Drug Discov. 2022 Nov 14:1-30. PMID: 36376561.
     

  11. Efficient combination in vivo RNAi of redundant synthetic lethal gene nodes.
    Amen AM, Loughran RM, Huang CH, Lew RJ, Guan Y, Emerling BM, and Fellmann C. Cell Rep Methods. 2022 Jun 21;2(7):100239. PMID: 35880017.
     

  12. A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients
    Pauli C, De Boni L, Pauwels JE, Chen Y, Planas-Paz L, Shaw R, Emerling BM, Grandori C, Hopkins BD, Rubin MA. Mol Cancer Res 2021 Nov 2. PMID: 34728552.
     

  13. Mechanistic roles of mutant p53 governing lipid metabolism
    Loughran RL and Emerling BM. Adv Biol Regul 2021 Nov 23:100839. PMID: 34840111. 
     

  14. Expanding role of PI5P4Ks in cancer: A promising druggable target
    Arora GK, Palamiuc L, Emerling BM. FEBS Lett 2022 Jan;596(1):3-16. PMID: 34822164. 
     

  15. Crucial Players for Inter-Organelle Communication: PI5P4Ks and Their Lipid Product PI-4,5-P2 Come to the Surface
    Ravi A, Palamiuc L, and Emerling BM. Front Cell Dev Biol 2022 Jan 7;9:791758. eCollection 2021.
     

  16. PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay. 
    Ravi A, Palamiuc L, Loughran RM, Triscott J, Arora GK, Kumar A, Tieu V, Pauli C, Reist M, Lew RJ, Houlihan SL, Fellmann C, Metallo C, Rubin MA, Emerling BM.  Dev Cell. 2021 Jun 7;56(11):1661-1676.e10. 
     

  17. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).  
    Klionsky DJ et al. Autophagy. 2021 Jan;17(1):1-382.
     

  18. ORP5 regulates PI(4)P on the lipid droplet: Novel players on the monolayer.
    Renne MF, Emerling BM.  J Cell Biol. 2020 Jan 6;219(1). 
     

  19. Phosphoinositides in Autophagy: Current Roles and Future Insights.
    Palamiuc, L , Ravi, A and Emerling, BM (2019). FEBS J. 2019.
     

  20. PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer.
    Palamiuc, L and Emerling, BM (2018). JEM. 2018; 215(1):17-29.
     

  21. Phosphatidylinositol-5-phosphate 4-kinases regulate cellular lipid metabolism by facilitating autophagy.
    Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Verma A, Yang Z, Johnson JL, Wong JCY, Ma Y, Weinkove D, Divecha N, Asara JM, Elemento O, Rubin MA, Kimmelman AC, Pause A, Cantley LC, and Emerling BM. (2018) Mol Cell. 70(3): 531-544. 
     

  22. PIP-ing Lipids on Membranes: PTEN takes the cake.
    Ravi A and Emerling, BM. (2017). Mol Cell. 2017; 68(3):471-472.
     

  23. Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.
    Shim H, Wu C, Ramsamooj S, Bosch KN, Chen Z, Emerling BM, Yun J, Liu H, Choo-Wing R, Yang Z, Wulf GM, Kuchroo VK, and Cantley LC. (2016) Proc Natl Acad Sci U S A. Jul 5; 113(27): 7596-601.
     

  24. The Lipid Kinase PI5P4Kβ Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis.
    Sumita K, Lo YH, Takeuchi K, Senda M, Kofuji S, Ikeda Y, Terakawa J, Sasaki M, Yoshino H, Majd N, Zheng Y, Kahoud ER, Yokota T, Emerling BM, Asara JM, Ishida T, Locasale JW, Daikoku T, Anastasiou D, Senda T, and Sasaki AT. (2016) Mol Cell. Jan 21; 61(2): 187-98.
     

  25. Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53 Null Tumors.
    Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Wulf G, Bell EL, Shim H, Choo-Wing R, Bellinger G, Lamia KA, Rameh LE, Sasaki A, Asara JM, Yuan X, Bullock A, Brown V, Signoretti S, and Cantley LC. (2013) Cell. Nov 7; 155(4): 844-57.
     

  26. A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation.
    Davis MI, Sasaki A, Shen M, Emerling BM, Cantley LC, Thorne N, Li Z, Pragani R, Boxer M, and Simeonov A. (2013) PLOS ONE. 8(1):e54127.

​

bottom of page